HD-OPM Archive
Topics › Aging & longevity

First epigenetic reprogramming trial in the eye; cardiovascular use is speculative

Louis Nervegna · Jun 11, 2026 · ♥ 26 reactions · 8 comments · original Facebook post
Aging & longevityCardiovascular disease: the big picture
AI summary & key facts

Louis comments on the start of a clinical trial using Yamanaka-factor epigenetic reprogramming to restore youthful cell states in the eye. The eye is the testing site because it is isolated from the body by the blood-ocular barrier, limiting cancer risk. He says if it works and is safe, cardiovascular regeneration could follow, which is speculation.

If this works and proves safe (a big if), it would be just a matter of time before it was also tested to regenerate the cardiovascular system.

The technology is called epigenetic reprogramming. By transiently activating certain genes within cells (the so-called Yamanaka factors), it partially reprograms cells to a more youthful state. These reprogrammed cells are largely indistinguishable from genuinely younger cells.

One of the main risks is the potential to cause cancer. That’s why they are testing it in the eye first. The eye is isolated from the rest of the body by the blood-ocular barrier. Any viral-based gene therapy delivered to the eye is very likely to stay in the eye. So potential harm would only occur inside the eye itself, and not the rest of the body.

Quoted:

An eagerly awaited and controversial clinical trial to 'wind back the clock' on aging cells in the eye and restore them to a more youthful state has officially begun.

This week, the United States biotechnology company Life Biosciences, Inc. announced that it had dosed its first patient with an experimental therapy designed to reverse age-related vision loss.

The ambitious idea is to turn back aging by activating three genes in retinal ganglion cells, which connect the brain to the eyes.

These nerves do not naturally regenerate. If they are damaged by disease, like glaucoma, it can lead to sudden and symptomless vision loss that is ultimately permanent.

An experimental therapy, called ER-100, is now being tested in humans to reverse the irreversible.

But whether it should be happening at all is up for debate.

The hope is that a single injection of the gene therapy, along with several weeks of antibiotics, could preserve or even restore vision in those who have lost sight in one or both eyes.

It's one of the most anticipated clinical trials of the year, and some think it could be a pivotal moment for the field of longevity research.

Other scientists argue it is "extraordinarily high-risk" and are skeptical it will work at all.

#epigeneticreprogrammingHD #davidsinclairHD #lifebiosciencesHD #er100HD #epigeneticsHD #epigeneticclockHD

ScienceAlertWorld First: Patient Receives High-Risk Therapy to Make Cells Young AgainAn eagerly awaited and controversial clinical trial to 'wind back the clock' on aging cells in the eye and restore them to a more youthful state has officially begun.sciencealert.com
← newer: Twice-weekly resistance training reversed prediabetes in a tolder: Vitamin D receptor agonist plus chemotherapy proved safe in →